ライフサイエンスコーパス: fatigue syndrome

1 ome), and malaise/fatigue (including chronic fatigue syndrome).

2 ostpoliomyelitis, poststroke, and in chronic fatigue syndrome.

3 gnostic criteria for neurasthenia or chronic fatigue syndrome.

4 the current state of knowledge about chronic fatigue syndrome.

5 oes not seem to be beneficial in the chronic fatigue syndrome.

6 relaxation therapy for patients with chronic fatigue syndrome.

7 tant in both chronic fatigue and the chronic fatigue syndrome.

8 There is mild hypocortisolism in chronic fatigue syndrome.

9 ctor contributing to the symptoms of chronic fatigue syndrome.

10 of well-characterized patients with chronic fatigue syndrome.

11 such as irritable bowel syndrome and chronic fatigue syndrome.

12 drome, heat intolerance, and perhaps chronic fatigue syndrome.

13 hysical disability for patients with chronic fatigue syndrome.

14 documented in both fibromyalgia and chronic fatigue syndrome.

15 documented in both fibromyalgia and chronic fatigue syndrome.

16 virus and Still's disease as well as chronic fatigue syndrome.

17 ic stress disorder, and possibly the chronic fatigue syndrome.

18 tibodies in sera of 60 patients with chronic fatigue syndrome.

19 dence for an autoimmune component in chronic fatigue syndrome.

20 bilitating symptoms of patients with chronic fatigue syndrome.

21 osis in the bigger context of the post-viral fatigue syndrome.

22 during the acute phase leading to post-viral fatigue syndrome.

23 cidality adequately in patients with chronic fatigue syndrome.

24 e entry) and received a diagnosis of chronic fatigue syndrome.

25 T and SMC plus GET for patients with chronic fatigue syndrome.

26 apy (APT) plus SMC and SMC alone for chronic fatigue syndrome.

27 rpetuating fatigue and disability in chronic fatigue syndrome.

28 iating symptoms of depression and in chronic fatigue syndrome.

29 vation approached levels observed in chronic fatigue syndrome.

30 le bowel syndrome, fibromyalgia, and chronic fatigue syndrome.

31 iated with human prostate cancer and chronic fatigue syndrome.

32 able to previously described post-infectious fatigue syndrome.

33 medical care (SMC) for patients with chronic fatigue syndrome.

34 ation with human prostate cancer and chronic fatigue syndrome.

35 rus linked to prostate carcinoma and chronic fatigue syndrome.

36 n the human gammaretrovirus XMRV and chronic fatigue syndrome.

37 r postinfectious irritable bowel and chronic fatigue syndromes.

38 logical distress in chronic pain and chronic fatigue syndromes.

39 attributable to the chronic pain and chronic fatigue syndromes.

40 prostate cancer and in patients with chronic fatigue syndromes.

41 physical functioning in people with chronic fatigue syndrome 1 year after randomisation.

42 An empirically defined fatigue syndrome 6 months after onset, which excluded co

43 athy, 463; myalgic encephalomyelitis/chronic fatigue syndrome, 95; preload failure, 120; post-treatme

44 The predictors of a prolonged fatigue syndrome after an infection differ with both def

45 The chronic fatigue syndrome also presents problems in definition an

46 ation with human prostate cancer and chronic fatigue syndrome, although these associations are contro

47 s meeting international criteria for chronic fatigue syndrome and 329 participants meeting London cri

48 121 consecutive clinic patients with chronic fatigue syndrome and 64 comparison subjects without the

49 ic biomarker of MMF in patients with chronic fatigue syndrome and cognitive dysfunction.

50 confirmed an association between the chronic fatigue syndrome and orthostatic intolerance; however, t

51 l microbiome have been identified in chronic fatigue syndrome and other neuropsychiatric disorders, a

52 ymptoms of myalgic encephalomyelitis/chronic fatigue syndrome and other post-acute infectious syndrom

53 es such as myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia sy

54 es such as myalgic encephalomyelitis/chronic fatigue syndrome and postural orthostatic tachycardia sy

55 coronary heart disease, cancer, and chronic fatigue syndrome and those remaining on their initial re

56 sought predictors of both acute and chronic fatigue syndromes and mood disorders from clinical, labo

57 ine and fibromyalgia', 'Dopamine and chronic fatigue syndrome' and 'Dopamine and irritable bowel synd

58 clear envelope proteins was found in chronic fatigue syndrome, and an increased prevalence of antipol

59 ssants for irritable bowel syndrome, chronic fatigue syndrome, and chronic back pain were selected fo

60 iated with type I diabetes, obesity, chronic fatigue syndrome, and various manifestations of inflamma

61 tation, evaluation, and prognosis of chronic fatigue syndrome are discussed.

62 C to moderately improve outcomes for chronic fatigue syndrome, but APT is not an effective addition.

63 an effective and safe treatment for chronic fatigue syndrome, but it is therapist intensive and avai

64 d all-cause mortality in people with chronic fatigue syndrome, but our findings show a substantial in

65 GET) can be effective treatments for chronic fatigue syndrome, but patients' organisations have repor

66 in blood samples from patients with chronic fatigue syndrome, but these findings have not been repli

67 Cognitive behavior therapy for chronic fatigue syndrome can produce some lasting benefits but i

68 ss in a case series of patients with Chronic Fatigue Syndrome (CFS) after the infection.

69 rlapping with those characterised as chronic fatigue syndrome (CFS) and have been described as CFS-li

70 1994 criteria were used to diagnose chronic fatigue syndrome (CFS) and idiopathic chronic fatigue (I

71 Fibromyalgia (FM) and chronic fatigue syndrome (CFS) are associated with substantial p

72 Patients with chronic fatigue syndrome (CFS) are more likely than healthy pers

73 in the blood of 67% of patients with chronic fatigue syndrome (CFS) compared with 3.7% of healthy con

74 nt reports showed many patients with chronic fatigue syndrome (CFS) harbor a retrovirus, xenotropic m

75 Chronic Fatigue Syndrome (CFS) has been defined as unexplained r

76 Gulf War Illness (GWI) and Chronic Fatigue Syndrome (CFS) have similar profiles of pain, fa

77 ogy, and treatment of postinfectious chronic fatigue syndrome (CFS) in adolescents.

78 associated with prostate cancer and chronic fatigue syndrome (CFS) in recent years.

79 sorder (PTSD) and illness resembling chronic fatigue syndrome (CFS) in the entire population of Gulf

80 Chronic fatigue syndrome (CFS) is a complex, heterogeneous disea

81 ncephalomyelitis (ME), also known as Chronic Fatigue Syndrome (CFS) is a debilitating condition.

82 Chronic fatigue syndrome (CFS) is a debilitating disease of unkn

83 Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is a debilitating multisystem con

84 Chronic fatigue syndrome (CFS) is a disabling condition with unk

85 Chronic fatigue syndrome (CFS) is a multisystem disorder charact

86 Chronic fatigue syndrome (CFS) is a serious systemic illness of

87 Chronic fatigue syndrome (CFS) is an important public health pro

88 Chronic fatigue syndrome (CFS) is associated with a dysregulated

89 is of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is based on clinical criteria, ye

90 Chronic fatigue syndrome (CFS) is characterized by severe fatigu

91 The pathogenesis of Chronic Fatigue Syndrome (CFS) is yet unknown.

92 Das Gupta, analyzed DNA samples from chronic fatigue syndrome (CFS) patients and healthy controls.

93 ifferences in the immune function of chronic fatigue syndrome (CFS) patients are detectable in rigoro

94 Chronic fatigue syndrome (CFS) patients often suffer from severe

95 Chronic fatigue syndrome (CFS) remains poorly understood.

96 te sinusitis (n = 25), subjects with chronic fatigue syndrome (CFS) with nonallergic rhinitis (n = 14

97 riterion for Gulf War Illness (GWI), Chronic Fatigue Syndrome (CFS), and fibromyalgia (FM).

98 ction may be common in patients with chronic fatigue syndrome (CFS).

99 d in the treatment and management of chronic fatigue syndrome (CFS).

100 kine, is suspected to play a role in chronic fatigue syndrome (CFS).

101 fatigue, a small number suffer from chronic fatigue syndrome (CFS).

102 hed criteria used to define cases of chronic fatigue syndrome (CFS).

103 es of myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS).

104 r to those reported by patients with chronic fatigue syndrome (CFS).

105 with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS).

106 in a high percentage of humans with chronic fatigue syndrome (CFS).

107 clear cells (PBMCs) of patients with chronic fatigue syndrome (CFS).

108 resent in the blood of patients with chronic fatigue syndrome (CFS).

109 have been controversially linked to chronic fatigue syndrome (CFS).

110 pears to be a potent risk factor for chronic fatigue syndrome (CFS).

111 Certain infections can trigger chronic fatigue syndromes (CFS) in a minority of people infected

112 s were recruited from six specialist chronic fatigue syndrome clinics in the UK National Health Servi

113 understanding the pathophysiology of chronic fatigue syndrome continue to demonstrate the involvement

114 o, 2.32 [95% CI, 1.02 to 5.27]); the chronic fatigue syndrome (deployed, 1.6%; nondeployed 0.1%; odds

115 measures included fibromyalgia, the chronic fatigue syndrome, dermatologic conditions, dyspepsia, ph

116 Patients with chronic fatigue syndrome experience significant functional impai

117 The prevalence of fatigue syndromes fell from 7.99 to 1.69 as somatic crit

118 Conditions examined were the chronic fatigue syndrome, fibromyalgia, the irritable bowel synd

119 We identified 2147 cases of chronic fatigue syndrome from CRIS and 17 deaths from Jan 1, 200

120 lth and Care Excellence criteria for chronic fatigue syndrome from two secondary-care clinics in the

121 Although chronic fatigue syndrome has significant symptom overlap and com

122 Turner syndrome, Williams syndrome, chronic fatigue syndrome, IgA nephropathy, and IgA deficiency.

123 12 as part of the Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Int

124 tality in individuals diagnosed with chronic fatigue syndrome in secondary and tertiary care using da

125 m', 'Functional somatic syndromes', 'Chronic fatigue syndrome', 'Irritable bowel syndrome', 'Fibromya

126 Chronic fatigue syndrome is a controversial condition especially

127 across many domains, suggesting that chronic fatigue syndrome is a heterogeneous condition of complex

128 Chronic fatigue syndrome is an illness characterized by disablin

129 Myalgic encephalomyelitis/chronic fatigue syndrome is an unexplained debilitating disorder

130 Chronic fatigue syndrome is diagnosed on the basis of symptoms.

131 The prevalence of chronic fatigue syndrome is much less than that of fibromyalgia.

132 the pathophysiology and treatment of chronic fatigue syndrome is reviewed.

133 Treatment for chronic fatigue syndrome is symptom-based and includes pharmacol

134 Mortality associated with chronic fatigue syndrome is uncertain.

135 Chronic fatigue syndrome is unlikely to be caused or maintained

136 Reports of mild hypocortisolism in chronic fatigue syndrome led us to postulate that low-dose hydro

137 erception of health as fair or poor, chronic fatigue syndrome-like illness, and posttraumatic stress

138 Myalgic encephalomyelitis/chronic fatigue syndrome-like symptoms, upper respiratory sympto

139 yalgic encephalomyelitis also called chronic fatigue syndrome linked to a viral and autoimmune pathog

140 I) such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Long-COVID, and Gulf War Illness (GWI)

141 In some patients with chronic fatigue syndrome, low-dose hydrocortisone reduces fatigu

142 nce also is beginning to emerge that chronic fatigue syndrome may be familial.

143 essment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM), we relied on expert clinician d

144 Myalgic encephalomyelitis/chronic fatigue syndrome (ME) is a severe, debilitating disease,

145 esearch of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM), two acq

146 ID (LC), Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) and healthy control subjects.

147 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID are persistent

148 iving with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) experience heterogeneous and d

149 es such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) have long been linked to infec

150 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) involves severe fatigue, unref

151 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) involves severe fatigue, unref

152 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic and debilitating

153 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic debilitating cond

154 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic illness with a mu

155 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex chronic disease,

156 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease character

157 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease with no k

158 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex heterogeneous mul

159 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex multisystem illne

160 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, debilitating dis

161 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating multisystemi

162 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a highly debilitating disea

163 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a medically unexplained ill

164 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is characterized by various di

165 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is commonly associated with co

166 tiology of myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is unknown, but involvement of

167 Myalgic Encephalomyelitis or chronic fatigue syndrome (ME/CFS) lacks objective diagnostic tes

168 GO-ME/CFS) myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) manifest similar symptoms, it

169 licated in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) pathogenesis.

170 agement of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a disabling long-term conditi

171 tures with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), suggest the potential involve

172 ts with myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), the data are limited and cont

173 with PASC, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), though studies have yielded m

174 pletion in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

175 ering from myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

176 inition of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

177 niscent of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

178 resembling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

179 seases and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

180 tates have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

181 o diagnose myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

182 chizophrenia (SZ), anxiety disorder, chronic fatigue syndrome, multiple sclerosis, amyotrophic latera

183 Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a

184 Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a

185 is marketed as a diagnostic test for chronic fatigue syndrome/Myalgic Encephalomyelitis (CFS/ME).

186 the following 5 groups of patients: chronic fatigue syndrome (n = 32), human immunodeficiency virus

187 nesis of non-GI autoimmune diseases, chronic fatigue syndrome, obesity and even some neuropsychiatric

188 ation between XMRV and patients with chronic fatigue syndrome or chronic immunomodulatory conditions.

189 hat predicted either the empirically defined fatigue syndrome or mood disorders.

190 Chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME) i

191 ssociated syncope, eating disorders, chronic fatigue syndrome, or history of congenital heart disease

192 cancer patients and in the blood of chronic fatigue syndrome patients.

193 infectious myalgic encephalomyelitis/chronic fatigue syndrome (PI-ME/CFS) is a disabling disorder, ye

194 n-diagnosed multisymptom conditions: chronic fatigue syndrome, posttraumatic stress disorder, multipl

195 elop chronic fatigue, referred to as Q fever fatigue syndrome (QFS).

196 cancer and myalgic encephalomyelitis/chronic fatigue syndrome, recent data indicate that results inte

197 ificantly lower in the subjects with chronic fatigue syndrome regardless of the presence or absence o

198 way in which chronic fatigue and the chronic fatigue syndrome relate to each other: Is one the severe

199 virus (XMRV) in prostate cancer and chronic fatigue syndrome reported in previous studies remains co

200 Trans-NIH Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Research Working Group.

201 The assessment and treatment of chronic fatigue syndrome should be multidimensional and tailored

202 increased risk for fibromyalgia, the chronic fatigue syndrome, skin conditions, dyspepsia, and a clin

203 ations are a cause or consequence of chronic fatigue syndrome still remains unanswered.

204 health, or had a history of obesity, chronic fatigue syndrome, substance abuse, an eating disorder, o

205 T cells and B cells of patients with chronic fatigue syndrome, suggesting an association between XMRV

206 ed whether narrow definitions of unexplained fatigue syndromes that require additional minor somatic

207 Definitions of unexplained fatigue syndromes that require more somatic criteria sel

208 War syndrome, chronic whiplash, the chronic fatigue syndrome, the irritable bowel syndrome, and fibr

209 e, and this is probably true for the chronic fatigue syndrome, too.

210 MRV, in blood cells of patients with chronic fatigue syndrome," two of the coauthors, Silverman and D

211 d rest were associated with, or predicted, a fatigue syndrome up to 2 months after onset.

212 esearch on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome was cosponsored by the NIH Office of Di

213 herapy versus relaxation therapy for chronic fatigue syndrome were invited to complete self-rated mea

214 patients meeting Oxford criteria for chronic fatigue syndrome were recruited from six secondary-care

215 reener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months

216 0.60-2.73; p=0.45) in patients with chronic fatigue syndrome when compared with the general populati

217 y research supports the notion of a discrete fatigue syndrome which can be distinguished from depress

218 patients meeting Oxford criteria for chronic fatigue syndrome who were recruited from six secondary c

219 ticipate that discrete causes of the chronic fatigue syndrome will be found in the future, even if th

220 patients met our strict criteria for chronic fatigue syndrome without co-morbid psychiatric disorder.